All In Biotech

Drug Trial Radar · NCT07206849

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

A Phase 2 Study of Tovorafenib in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor Alterations in the Mitogen-Activated Protein Kinase (MAPK) Pathway

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

79

Planned (sponsor's estimate)

Start

Feb 2027

Primary completion

Feb 2030

Study completion Feb 2037

Sponsor

Lead sponsor
Nationwide Children's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Day One Biopharmaceuticals, Inc.
First posted
Oct 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 39 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to determine the efficacy of the study drugs tovorafenib to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (MAPK) that this drug targets. The main question the study aims to answer is whether tovorafenib can prolong the life of patients diagnosed with HGG, including DIPG.

Conditions

  • High Grade Glioma (HGG) of the Brain With BRAF Aberration
  • High Grade Glioma (III or IV)
  • Diffuse Intrinsic Pontine Glioma
  • High Grade Glioma
  • WHO Grade 3 Glioma
  • WHO Grade 4 Glioma
  • Metastatic Brain Tumor

Interventions

  • TovorafenibDrug

    Tovorafenib will be given orally once weekly (QW) throughout each cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival Stratum ATime frame: 6 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.